Secondary prophylaxis decreases the rate of relapse to less than 5% in HIV/AIDS patients [60].The IDSA recommends that after a minimum of 12 months of antifungal therapy during ART, the discontinuation of suppressive antifungal therapy can be considered in patients with a CD4 count > 100 cells/μL and an undetectable or very low HIV RNA level sustained for ≥3 months. Here, CD4 is linked to AIDS.